Asian Liquidity Stress Index
[Apr 19] Moody's Asian Liquidity Stress Index (LSI) deteriorated further in March and now stands at 15.5%, with 15 of 97 issuers in the speculative-grade portfolio demonstrating weak liquidity, compared with 14.6%, or 14 out of 96 issuers, in February.
Global Industry Outlooks
[Apr 24] Weak business sentiment in Europe offset a modest recovery in the US during the first quarter, keeping the outlook for the global non-financial corporate sector largely intact for the next 12-18 months.
Global Pharmaceutical Industry
[Apr 19] The outlook for the global pharmaceutical industry remains negative as any potential revenue over the next 12-18 months is likely to be offset by losses from the upcoming expiries of major patents (known as 'the patent cliff').
Moody's Weekly Credit Outlook
[Apr 23] Pressure for Genworth and Queensland-Based Lenders; RBI's Rate Cut and Liquidity Support for Banks; and more.
CREDIT RATINGS ARE MIS'S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES. MIS DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL, FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. CREDIT RATINGS DO NOT CONSTITUTE INVESTMENT OR FINANCIAL ADVICE, AND CREDIT RATINGS ARE NOT RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. CREDIT RATINGS DO NOT COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MIS ISSUES ITS CREDIT RATINGS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.